In a groundbreaking move, Boston Scientific Corporation (NYSE: BSX) has recently announced its definitive agreement to acquire Axonics, Inc. (Nasdaq: NASDAQ:AXNX ), a pioneering medical technology company specializing in the development and commercialization of advanced devices to address urinary and bowel dysfunction. This strategic acquisition, valued at...
Promising biotech setup here, had a nice break of 70 recently and may be looking to go higher. Potentially risky if XBI rolls over but strong momentum here nonetheless. Good luck traders!
Surgical devices/equipment and surgically implanted devices may face a drastic increase in demand this coming quarter with the resumption of all elective procedures. During covid 19 many hospitals were forced to limit surgeries ( like insertions of AXNX's sacral neuromodulation device) to provide extra beds/resources to cope with the pandemics issues. A break...
Axonics Modulation Technologies AXNX is a medical device manufacture. They make a device that helps control overactive bladders. Their main competitor is NYSE:MDT , which makes a very similar device. The main reason this caught my eye is because of the newness factor. This device will help improve the quality of life of the person whose body keeps telling...
Saw my alert come up and watched it break first 5m. Bought at the pullback on the BO level with a 1DATR stop. Tighted stops to BE after the huge volume came in pushing it to ATH.
NASDAQ:AXNX
Well, another good candidate to buy in the coming days.
What's on the chart:
1. Strong 40.40 level, formed on May 19.
2. The level is enhanced by false breakouts and a round number.
3. A series of retests.
4. Two false breakouts of 08.06 and 17.06 showed us a reaction and the instrument went down,
but we didn't go into the short zone.
5. The...
Hi, today we are going to talk about Axonics Modulation Technologies and its current landscape.
Axonics Modulation is poised to receive increasing attention from the market as relevant events are taking place. The medical technology company announced that it received permission for nine patents related to its implantable sacral neuromodulation technology, which...
AXNX big range break today for the recent IPO, $435M maker of sacral neuromodulation solutions for overactive bladders and urinary retention. AXNX presented positive data this morning and will report on 3-5. It is an early-stage med-tech Co. with $6.9M in revenues seen for 2019 but forecasts calling for $200M+ by 2022.
